Generic Name

Mebeverine Hydrochloride

Precaution

Caution should be exercised in porphyria or allergic reaction to this or any other medicine of this group.

Indication

Irritable bowel syndrome (IBS), GI tract spasm

Contra Indication

Paralytic ileus.

Dose

N/A

Side Effect

Dizziness, headache, GI disturbances, insomnia, anorexia, decreased heart rate, hypersensitivity (e.g. urticaria, erythematous rash, angioedema).

Pregnancy Category

Mode of Action

Mebeverine is an antispasmodic agent which exerts direct action on the GI smooth muscle.

Interaction

N/A

Pregnancy Category Note

Pregnancy Contraindicated during pregnancy; avoid pregnancy for 3 months following vaccination In a 10-year survey involving over 700 pregnant women who received rubella vaccine within 3 months before or after conception (of whom 189 received the Wistar RA 27/3 strain), none of the newborns had abnormalities compatible with congenital rubella syndrome Mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion Although mumps vaccine virus has been shown to infect the placenta and fetus, there is no evidence that it causes congenital malformations in humans Reports have indicated that contracting wild-type measles during pregnancy enhances fetal risk; increased rates of spontaneous abortion, stillbirth, congenital defects and prematurity have been observed subsequent to infection with wild-type measles during pregnancy There are no adequate studies of the attenuated (vaccine) strain of measles virus in pregnancy; however, it would be prudent to assume that the vaccine strain of virus is also capable of inducing adverse fetal effects Lactation Unknown if measles or mumps vaccine is secreted in human milk The prescribing information describes studies that have shown lactating postpartum women immunized with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breastfed infants

Adult Dose

Oral Irritable bowel syndrome; Gastrointestinal tract spasm Adult: Tablet 135 mg tid, may reduce gradually after several wk when the desired effect has been obtained; As modified-release Capsule: 200 mg bid.

Child Dose

N/A

Renal Dose

N/A

Administration

N/A